Product
Gantenerumab
Aliases
RO4909832
10 clinical trials
4 indications
Indication
Alzheimer's diseaseIndication
Alzheimer's DiseaseIndication
DementiaIndication
FamilialClinical trial
A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Pharmacodynamic Effects of Once Weekly Administration of Gantenerumab in Participants With Early (Prodromal to Mild) Alzheimer's DiseaseStatus: Terminated, Estimated PCD: 2023-01-11
Clinical trial
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's DiseaseStatus: Terminated, Estimated PCD: 2022-09-23
Clinical trial
An Open-Label, Multicenter, Rollover Study to Evaluate the Safety and Tolerability of Long-Term Administration of Gantenerumab in Participants With Alzheimer's DiseaseStatus: Terminated, Estimated PCD: 2023-01-04
Clinical trial
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's DiseaseStatus: Terminated, Estimated PCD: 2022-12-28
Clinical trial
An Open-Label, Multicenter, Rollover Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's DiseaseStatus: Terminated, Estimated PCD: 2023-03-06
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Study of Gantenerumab in Patients With Mild Alzheimer's Disease; Part II: Open-Label Extension For Participating PatientsStatus: Completed, Estimated PCD: 2021-04-16
Clinical trial
A Phase III, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's DiseaseStatus: Terminated, Estimated PCD: 2023-03-10
Clinical trial
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled, Two-part Adaptive Design, Platform Trial of Investigational Treatments for Primary Prevention of Disease Progression in Dominantly Inherited Alzheimer's DiseaseStatus: , Estimated PCD: 2029-11-01
Clinical trial
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's DiseaseStatus: Recruiting, Estimated PCD: 2027-10-01
Clinical trial
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's DiseaseStatus: Terminated, Estimated PCD: 2023-08-12